Search
Along with founding partner Equinox, Cycle for Survival begins its signature team stationary-cycling events this week in New York City. 100% of funds raised go directly to rare cancer research at Memorial Sloan Kettering Cancer Center (MSK).
If you've been treated for soft tissue sarcoma, a recurrence may be a big concern for you. Here's what MSK's sarcoma experts think you should know about the disease coming back.
Cytoreductive surgery for advanced ovarian cancer is safe in older women, even those who present with frailty.
Memorial Sloan Kettering Cancer Center (MSK) is now recognized as the first dedicated cancer center in the United States to be designated as a qualified provider-led entity (QPLE) under Medicare’s program for appropriate use criteria (AUC). This designation allows MSK to establish best practice standards for the use of CT scans, MRI, and nuclear medicine imaging from initial screening and diagnosis through all stages of cancer care, including survivorship.
Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards.
Research led by Josie Robertson Investigator Karuna Ganesh provided clues that microbiomes might explain the increase in colorectal cancer among younger patients.
A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research.
Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.
Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.
Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).